Heath Ingram is an attorney for life sciences and healthcare companies, including biotechnology companies, pharmaceutical and medical device manufacturers, and digital health companies at all stages of development, as well as, venture capital and private equity firms focused on all aspects of the healthcare industry. Heath is based in New York, and is a member of Goodwin’s Life Sciences group and Healthcare practice.

Heath focuses his practice on healthcare regulatory, transactional, compliance, enforcement, investigations, and government advocacy matters.

He has experience with a broad range of healthcare matters including: fraud and abuse risk under the federal Anti-kickback Statue and Stark Law; value-based contracting; managed care contracting; market access matters; drug price transparency laws; reporting under the Sunshine Act; counseling on patient assistance programs; government price reporting; the 340B Drug Pricing Program; Medicare and Medicaid coverage and reimbursement; healthcare licensure; patient privacy; government investigations; and internal investigations. 

Heath maintains an active pro bono practice and serves as a lead outside counsel to The Trevor Project, the world’s largest suicide prevention and crisis intervention organization for LGBTQ young people.

Heath received his J.D. cum laude, from the Northwestern University School of Law while simultaneously earning his M.A. in Medical Humanities and Bioethics from Northwestern, where he focused his graduate thesis on precision medicine, genetics, and the law. While at Northwestern, he worked for Judge Gary Feinerman of the Northern District of Illinois and completed a Graduate Fellowship with the National Immigrant Justice Center in Chicago. Heath graduated summa cum laude and Phi Beta Kappa from Miami University and is a former member of the Miami University Board of Trustees.





Mr. Ingram’s recent experience includes:

Representative Matters



  • Serving as day-to-day fraud and abuse counsel to several medical device manufacturers by providing analysis of discount and rebate arrangements with customers, sales and marketing practices, financial arrangements with healthcare professionals, preparing policies and procedures, assisting with internal training and compliance matters;
  • Counsels drug manufacturers on strategic approaches to compliance with all state drug transparency laws and regularly presents and publishes on new developments in these state laws;
  • Regularly conducts regulatory due diligence reviews for numerous life sciences transactions, including mergers and acquisitions on behalf of private equity firms, and in connection with IPOs and SPACs, and advise clients on fraud and abuse, compliance, licensure, corporate practice of medicine, HIPAA, change of ownership, and other healthcare issues;
  • Regularly advises both prominent and emerging pharmaceutical, biotechnology, and medical device manufacturers on strategic approaches to Sunshine Act compliance;
  • Negotiated and advised on numerous managed care and rebate agreements with pharmacy benefit managers, payors, and group purchasing organizations, on behalf of both emerging and prominent manufacturers;
  • Advised company on strategic approaches to compliance with all aspects of the 340B Drug Pricing Program and integration of the 340B Drug Pricing Program into the company’s business model.
Mergers and Acquisitions
  • Advised AbCellera, a technology company with a centralized operating system for next-generation antibody discovery, on its all-cash acquisition of TetraGenetics, a biotech company generating recombinant human ion channels and other transmembrane proteins;
  • Advised Chiasma, Inc., a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies for rare and serious chronic diseases, on its definitive agreement to be acquired by Amryt Pharma plc in an all-stock combination;
  • Advised initial purchasers J.P. Morgan Securities LLC and SVB Leerink LLC on MannKind Corporation’s (a biopharmaceutical company focused on the development of therapeutic products for chronic conditions) Rule 144A offering of $230 million 2.5% Convertible Senior Notes Offering;
  • Advised Kingswood Capital Management, LP, a private investment firm primarily focused on investing in businesses in transition, in connection with its acquisition of Cost Plus World Market from Bed Bath and Beyond Inc;
  • Advised Collective Medical Technologies, a real-time care collaboration network used by payors and healthcare organizations to improve patient outcomes, in connection with its sale to PointClickCare Corp. for approximately $600 million.
Capital Markets
  • Advised Galecto, Inc., a biotechnology company, in its sales agreement with Jeffries LLC providing for the sale of $50 million of Galecto’s common stock in “at-the-market” transactions;
  • Advised Absci Corporation, an AI-powered synthetic biology company, in its $230 million initial public offering;
  • Advised underwriters in Rapid Micro Biosystems’, a life sciences technology company providing automation solutions for healthcare products, in its $158.4 million initial public offering;
  • Advised Centessa Pharmaceuticals in its $379.5 million initial public offering;
  • Advised Graphite Bio, a gene editing company, in its $273.7 million initial public offering;
  • Advised Cerevel Therapeutics, a biopharmaceutical company developing treatments for neuroscience diseases, in its $350 million initial public offering;
  • Advised Aerovate Therapeutics, a biopharmaceutical company focused on developing drugs for cardiopulmonary disease, in its $139.8 million initial public offering;
  • Advised Chardan Capital Markets as underwriters in Femasys’ (a biomedical company focused on women’s healthcare) $34.45 million initial public offering;
  • Advised Goldman Sachs and Co. as lead underwriter in Valneva’s (a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases and COVID-19) $107.6 million initial public offering;
  • Advised Goldman Sachs and Co. and J.P. Morgan as underwriters in Privia Health Group, Inc.’s (a technology-driven, national physician enablement company) $131.7 million initial public offering.
Enforcement and Investigations
  • Represented a practice management company in a Department of Justice (DOJ) investigation involving allegations of “upcoding” and other alleged fraudulent billing and coding practices;*
  • Conducted multiple internal investigations on behalf of pharmaceutical drug and device manufacturers in response to allegations of violations of the Anti-Kickback Statute, the False Claims Act, and internal compliance violations;*
  • Represented a managed care organization in a False Claims Act investigation of its Medicare Advantage reimbursement and related practices in response to a DOJ Civil Investigative Demand.*

*Denotes experience prior to joining Goodwin. Prior to joining Goodwin, Heath was an Associate at Latham & Watkins.

Pro Bono
  • Serving as a lead outside counsel to The Trevor Project, the world’s largest suicide prevention and crisis intervention organization for LGBTQ young people, where he assists in negotiating service agreements, data privacy and security, healthcare regulatory issues, and employment law.
Professional Activities

Heath is a member of the American Health Law Association and the American Bar Association.


  • Short list, Chambers and Partners Diversity and Inclusion Award: 2019 Future Leader – LGBT+ Equality

In The News









J.D., 2016
Northwestern University Pritzker School of Law
(cum laude)
M.A., 2016
Northwestern University
B.A., 2011
Miami University
(summa cum laude, Phi Beta Kappa)



New York
District of Columbia
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique